Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (11), 6162-6177
- https://doi.org/10.1111/jcmm.15243
Abstract
In beta-thalassaemia, anaemia results from ineffective erythropoiesis characterized by inhibition of late-stage erythroid differentiation. We earlier used luspatercept and RAP-536 protein traps for certain Smad2/3-pathway ligands to implicate Smad2/3-pathway overactivation in dysregulated erythroid differentiation associated with murine beta-thalassaemia and myelodysplasia. Importantly, luspatercept alleviates anaemia and has been shown to reduce transfusion burden in patients with beta-thalassaemia or myelodysplasia. Here, we investigated the molecular mechanisms underlying luspatercept action and pSmad2/3-mediated inhibition of erythroid differentiation. In murine erythroleukemic (MEL) cells in vitro, ligand-mediated overactivation of the Smad2/3 pathway reduced nuclear levels of GATA-1 (GATA-binding factor-1) and its transcriptional activator TIF1 gamma (transcription intermediary factor 1 gamma), increased levels of reactive oxygen species, reduced cell viability and haemoglobin levels, and inhibited erythroid differentiation. Co-treatment with luspatercept in MEL cells partially or completely restored each of these. In beta-thalassaemic mice, RAP-536 up-regulated Gata1 and its target gene signature in erythroid precursors determined by transcriptional profiling and gene set enrichment analysis, restored nuclear levels of GATA-1 in erythroid precursors, and nuclear distribution of TIF1 gamma in erythroblasts. Bone marrow cells from beta-thalassaemic mice treated with luspatercept also exhibited restored nuclear availability of GATA-1 ex vivo. Our results implicate GATA-1, and likely TIF1 gamma, as key mediators of luspatercept/RAP-536 action in alleviating ineffective erythropoiesis.Funding Information
- Acceleron Pharmaceuticals
This publication has 54 references indexed in Scilit:
- Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemiaBlood, 2012
- β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolismBlood, 2011
- The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1γThe EMBO Journal, 2011
- TIF1γ Controls Erythroid Cell Fate by Regulating Transcription ElongationCell, 2010
- Chaperoning erythropoiesisBlood, 2009
- Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDSBlood, 2008
- IRF4 addiction in multiple myelomaNature, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- The Zebrafish moonshine Gene Encodes Transcriptional Intermediary Factor 1γ, an Essential Regulator of HematopoiesisPLoS Biology, 2004
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003